Amplia's Lilly Deal Opens a $31 Billion Lung Cancer Market - but ATX Investors Still Need Proof

Lilly partnership gives Amplia access to NSCLC, but only trial data can really reprice ATX

The partnership gives Amplia a foothold in NSCLC development; only trial data can truly reprice ATX.

Amplia has now moved into a development area tied to a global NSCLC market is currently valued at approximately US$31 billion through a Phase 1b/2b clinical trial using Eli Lilly's in-kind supply of olomorasib. That matters because NSCLC is large enough for investors to imagine a meaningful upside if narmafotinib earns a role in this setting. But a partnership by itself is not the same as licensed cash flow or a milestone payment. It is access to a important market and a clearer path to test whether the combination has clinical value.

The other benefit is capital efficiency. Lilly providing the drug at no cost reduces the direct drug-supply burden, and the study's expected late-2026 start gives investors a clear milestone to track. The fact that the companies already had an advanced draft of the protocol before signing also suggests the setup was progressing before the agreement was finalized. That is encouraging, but it is still preliminary.

Amplia will commence work in late 2026. Until that trial produces patient readouts, the Lilly relationship is best viewed as a doorway into a large lung cancer market, not proof of value.

Why the Lilly collaboration matters: the combination has a plausible biological rationale

This partnership matters because Lilly is not testing a random pairing. It is moving narmafotinib forward with olomorasib, a next-generation KRAS G12C inhibitor that is already in two separate, global Phase 3 registrational trials in NSCLC. That gives the combo more credibility than an ad hoc combination would have.

Why FAK plus KRAS inhibition is being explored

KRAS G12C mutations account for about 13% of NSCLC cases, but single-agent KRAS inhibition often stalls as tumors find ways around the block. Preclinical and translational work has identified FAK as a central mediator of adaptive resistance to KRAS G12C inhibition. In simple terms, some cancer cells appear to activate FAK as an escape route when KRAS is blocked, helping them survive.

That is why Amplia is testing the combination. Olomorasib targets the KRAS-driven signal, while narmafotinib, Amplia's investigational FAK blocker, is intended to help blunt that backup route. The aim is not simply more activity; it is to make the KRAS attack harder for the tumor to evade.

What would count as early success in this trial

This is a Phase 1b/2b clinical trial evaluating the combination as a second-line treatment for patients with advanced-stage NSCLC. So early success starts with basic feasibility: the regimen needs to be tolerable enough to keep studying, and it needs to show at least some hint of activity.

There is also an existing clinical reference point. Amplia says the ACCENT study showed no significant tolerability burden over chemotherapy alone, along with efficacy signals that supporters view as encouraging. If the NSCLC combination shows a similar pattern-manageable safety with signs the combo can shrink or stabilize disease-the program would be harder to dismiss.

Why NSCLC matters for Amplia's broader story

Narmafotinib already has visibility in pancreatic and ovarian cancer. NSCLC does not replace those programs; it expands them into a larger oncology market. The opportunity is bigger, but the burden of proof is the same: early data still need to support the concept before investors can treat this as more than an interesting expansion.

The bear case: Lilly's backing improves credibility, but it does not replace clinical proof

The bear case is not about Lilly's reputation. It is about what that reputation can and cannot do for Amplia right now. A big-pharma partnership can improve visibility, but it does not validate the asset until the trial runs cleanly and the data speak. That is the distinction investors need to keep in mind as the program moves toward the trial is slated to begin with Lilly providing olomorasib at no cost.

The real near-term test

Bears will also note that Amplia's share price is still likely to track clinical milestones, partnership progress, and trial execution. Investors are not buying installed revenue today. They are buying a sequence of checkpoints: protocol finalization, trial start, safety readouts, and evidence that the combination does more than look logical on paper.

That is why earlier narmafotinib data cuts both ways. The ACCENT dataset showed 36% response rate, 11.1-month median overall survival, and a 7.8% complete response rate. Those are real signals, not marketing copy. But bears are right on one important point: those figures came from an earlier setting, not from the NSCLC combination that now has the market's attention.

What investors should watch before the thesis gets stronger

From here, the job is to separate motion from evidence.

Near-term watchlist

• Protocol finalization: The next real catalyst is paperwork turning into a locked plan. Amplia and Lilly are still finalise the clinical study protocol, even though they already have an advanced draft. That is progress, not closure.
• Site setup across Australia and the US: Investors should look for signs that trial locations are becoming operational, not just mentioned in press material. Both companies have said the study will run at sites across Australia and the US.
• First-patient enrollment: That is the point at which the trial stops being planning and starts becoming evidence.
• Late-2026 start: The study is expected to begin in late 2026, and Amplia will commence work in late 2026. If that clock slips, the stock may stall even if the science still looks sound.

The proof point that matters most

The next true repricing event is the Phase 1b/2b trial in second-line advanced NSCLC. What investors need to see is straightforward: a tolerability profile that allows the study to continue, plus an early efficacy signal strong enough to make the larger NSCLC opportunity feel real rather than purely theoretical.

What would weaken the thesis quickly

If protocol work drags, site activation stays invisible, enrollment slips, the late-2026 start moves again, or the early data show too much toxicity or not enough activity, the thesis weakens quickly. For now, ATX still looks closely tied to clinical milestones, partnership progress, and trial execution.

Partnership headlines can open the door, but patient data is what will ultimately decide the story.